Phase 1
N=279
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
Fungal Infection
Bottom Line
View on ClinicalTrials.gov: NCT01075984 ↗Enrolled (actual)
279
Serious AEs
28.3%
Results posted
Nov 2013
Primary outcome: Primary: Single Dose Trough Concentration of IV Posaconazole (Cmin) — 318; 295; 467 ng/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Posaconazole (Drug); Dextrose 5% in water (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Nov 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Single Dose Trough Concentration of IV Posaconazole (Cmin) |
318; 295; 467 | — |
| PRIMARY Steady State Trough Concentration of IV Posaconazole (Cmin) |
958; 1046; 1164 | — |
| PRIMARY Single Dose Maximum Concentration of IV Posaconazole (Cmax) |
881; 990; 1590 | — |
| PRIMARY Steady State Maximum Concentration of IV Posaconazole (Cmax) |
1947; 2610; 3696 | — |
| PRIMARY Single Dose Time of Observed Maximum Concentration of IV Posaconazole (Tmax) |
1.42; 1.48; 1.54 | — |
| PRIMARY Steady State Time of Observed Maximum Concentration of IV Posaconazole (Tmax) |
1.00; 1.50; 1.52 | — |
| PRIMARY Single Dose Area Under the Concentration Versus Time Curve of IV Posaconazole (AUC) |
5940; 5390; 8240 | — |
| PRIMARY Steady State Area Under the Concentration Versus Time Curve of IV Posaconazole (AUC) |
28241; 33754; 37586 | — |
| PRIMARY Steady State Average Concentration of IV Posaconazole (Cavg) |
1180; 1410; 1566 | — |
| PRIMARY Steady State Total Body Clearance of IV Posaconazole (CL) |
— | — |
| PRIMARY Steady State Trough Concentration of Oral Posaconazole (Cmin) |
370; 532; 316 | — |
| PRIMARY Steady State Maximum Concentration of Oral Posaconazole (Cmax) |
494; 811; 430 | — |
| PRIMARY Steady State Time of Observed Maximum Concentration of Oral Posaconazole (Tmax) |
3.03; 3.05; 5.54 | — |
| PRIMARY Steady State Area Under the Concentration Versus Time Curve of Oral Posaconazole (AUC) |
5080; 6920; 3970 | — |
| PRIMARY Steady State Average Concentration of Oral Posaconazole (Cavg) |
423; 570; 331 | — |
| PRIMARY Steady State Apparent Total Body Clearance of Oral Posaconazole (CL/F) |
— | — |
Summary
The purpose of this study is to collect pharmacokinetic (PK) information related to how well intravenous Posaconazole (POS IV), is distributed in the body and to determine the safety and tolerability of this new formulation. In addition, the PK, safety, and tolerability of switching from taking POS IV to taking Posaconazole Oral Suspension (POS Oral) will be evaluated. The data collected in this study will be compared to data collected in previous studies.
Individuals who have been diagnosed by their physicians with a blood disease or cancer that can affect their infection-fighting white blood cells will be asked to participate in the trial. Since these blood diseases and their treatments can weaken the immune system, they may put these individuals at a high risk for getting a serious fungal infection of their internal organs or blood (invasive fungal infection). As these fungal infections can be hard to detect early and can be life-threatening, many physicians believe that individuals diagnosed with these diseases should receive antifungal therapy to try to lower their risk of getting this type of infection.
Enrollment into this study will take place in several stages (cohorts). The determination of which cohort an individual will be asked to participate in is based on which cohort is open at the site at the time the individual is approached to consider study participation.
Eligibility Criteria
Inclusion Criteria
- Adult subjects greater than or equal to 18 years of age (weighing greater than 34 kg [75 lb]), of either sex and of any race/ethnicity.
- Disease definition for each subject: Anticipated (likely to develop within 3 days to 5 days) or documented prolonged neutropenia (absolute neutrophil count [ANC] <500/mm^3 [0.5 x 10^9/L]) at Baseline and likely to last for at least 7 days due to:
- a. Standard intensive chemotherapy, anthracycline-based or other accepted regimen (excluding any investigational agent), for a new diagnosis of acute myelogenous leukemia (AML);
- b. Chemotherapy for AML in first relapse; or
- c. Therapy for myelodysplastic syndromes in transformation to AML or other diagnoses of secondary AML (therapy related, antecedent hematological disorders) or chronic myelogenous leukemia in blast crisis
- Disease definition for each Cohort 3 subject: In addition to subjects defined above, allogeneic hematopoietic stem cell transplant (HSCT) subjects may be randomized in either the pre-engraftment period (i.e., after they have received their conditioning regimen for the transplant, but while they are still neutropenic) or in the post-engraftment period if they are receiving immunosuppressive therapy for prevention or treatment of graft-versus-host disease (e.g., steroids, tacrolimus, cyclosporin, mycophenolate mofetil, and antithymocyte globulin).
Exclusion Criteria
- A female subject must not be pregnant, must not intend to become pregnant during the study, or must not be nursing.
- Excluded prior treatments. A subject must not have received systemic antifungal therapy (oral, intravenous, or inhaled) for the treatment of proven or probable IFI within 30 days of Enrollment.
- A subject must not have moderate or severe liver dysfunction at Baseline, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than three times the upper limit of normal (ULN), AND a total bilirubin level greater than two times the ULN. For Cohorts 1 and 2, a subject must not have a known or suspected history of Gilbert's disease.
- A subject must not have an electrocardiogram (ECG) with a prolonged QTc interval by manual reading: QTc greater than 500 msec.
- A subject must not have prior enrollment in this study, or other POS studies within 90 days of study entry.
- A subject must not have a known or suspected invasive or systemic fungal infection at Baseline. Those subjects receiving empiric anti-fungal therapy within 7 days prior to Baseline must have had a diagnostic work-up that ruled out a possible invasive fungal infection.
- A subject must not have creatinine clearance levels (measured or calculated) below 50 mL/min.
- A subject must not have a history of Type I hypersensitivity or idiosyncratic reactions to azole agents.
Data sourced from ClinicalTrials.gov (NCT01075984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.